South32 (S32) Earns Buy Rating from UBS Group

Share on StockTwits

UBS Group restated their buy rating on shares of South32 (LON:S32) in a research report sent to investors on Friday, investing.thisismoney.co.uk reports.

S32 has been the subject of a number of other reports. Deutsche Bank reduced their target price on shares of South32 from GBX 230 ($3.01) to GBX 225 ($2.94) and set a buy rating for the company in a report on Friday, January 18th. Citigroup restated a buy rating and set a GBX 250 ($3.27) target price on shares of South32 in a report on Monday, December 10th. Barclays reaffirmed an overweight rating on shares of South32 in a research note on Friday, October 12th. Finally, HSBC decreased their price objective on shares of South32 from GBX 230 ($3.01) to GBX 220 ($2.87) and set a buy rating for the company in a research note on Friday, January 18th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. South32 presently has a consensus rating of Buy and a consensus target price of GBX 225 ($2.94).

Shares of LON:S32 opened at GBX 204 ($2.67) on Friday. South32 has a 1-year low of GBX 143.25 ($1.87) and a 1-year high of GBX 236 ($3.08).

South32 Company Profile

South32 Limited operates as a diversified metals and mining company primarily in Australia, Southern Africa, and South America. The company has a portfolio of assets producing alumina, aluminum, bauxite, energy and metallurgical coal, manganese ore and alloy, laterite ferronickel, silver, lead, and zinc.

See Also: Consumer Price Index (CPI)

Analyst Recommendations for South32 (LON:S32)

Receive News & Ratings for South32 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for South32 and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

InZinc Mining  Shares Up 28.6%
InZinc Mining Shares Up 28.6%
Cellular Biomedicine Group  Releases  Earnings Results
Cellular Biomedicine Group Releases Earnings Results
Cincinnati Financial Co.  Director Dirk J. Debbink Acquires 351 Shares
Cincinnati Financial Co. Director Dirk J. Debbink Acquires 351 Shares
Insider Selling: Paratek Pharmaceuticals Inc  Director Sells 3,375 Shares of Stock
Insider Selling: Paratek Pharmaceuticals Inc Director Sells 3,375 Shares of Stock
PS Business Parks  Posts  Earnings Results, Misses Expectations By $0.48 EPS
PS Business Parks Posts Earnings Results, Misses Expectations By $0.48 EPS
Yamana Gold Inc.  Senior Officer Richard Campbell Sells 12,776 Shares of Stock
Yamana Gold Inc. Senior Officer Richard Campbell Sells 12,776 Shares of Stock


Leave a Reply

© 2006-2019 Ticker Report